Status:
ENROLLING_BY_INVITATION
Effect of Omega-3 Supplementation on Pregnant Outcomes and Inflammation Markers of Women Infected With HIV Using Antiretroviral Therapy
Lead Sponsor:
Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
Conditions:
Pregnant HIV Positive Women
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
This clinical trial aims to determine the effect of PUFA-n3 supplementation on birth weight, gestational length, and plasma inflammatory markers in pregnant women with HIV who are on antiretroviral th...
Detailed Description
In pregnant women infected with human immunodeficiency virus (HIV), antiretroviral therapy (ART) during pregnancy significantly reduces the risk of neonatal or vertical transmission of the virus. Howe...
Eligibility Criteria
Inclusion
- Pregnant women
- Single pregnancy
- Gestational age from 20 to 29 weeks since the first day of the last menstrual period
- Agree to participate in the study
Exclusion
- Gestational age more than 29 weeks
- With diagnosis of gestational diabetes or preeclampsia
- Smoking and/or drug use during the invitation to participate in the study
- Fish allergy
Key Trial Info
Start Date :
May 14 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2029
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT06971445
Start Date
May 14 2025
End Date
December 1 2029
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Perinatologia
Mexico City, Mexico City, Mexico, 11000